Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last4,421 to 4,440 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Distress Screening vs No Screening: deaths from any cause | 25 of 744 16 of 692 | 1.0 points -0.7 to 2.8 | 1,436 | NCT02941614 Implementing Systematic Distress Screening in Breast Cancer |
| Continuous Hormonal Therapy vs Intermittent Hormonal Therapy: serious adverse events | 19 of 732 10 of 702 | 1.2 points -0.3 to 2.7 | 1,434 | NCT00002651 SWOG-9346, Hormone Therapy in Treating Men With Stage IV Prostate Cancer |
| Donepezil SR 23 mg vs Donepezil IR 10 mg: serious adverse events | 80 of 963 45 of 471 | -1.2 points -4.6 to 1.8 | 1,434 | NCT00478205 Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease |
| Remote Ischemic Conditioning (RIC) vs Sham: deaths from any cause | 41 of 713 47 of 720 | -0.8 points -3.3 to 1.7 | 1,433 | NCT03481777 Remote Ischemic Conditioning in Patients With Acute Stroke (RESIST) |
| Remote Ischemic Conditioning (RIC) vs Sham: serious adverse events | 335 of 713 325 of 720 | 1.8 points -3.3 to 7.0 | 1,433 | NCT03481777 Remote Ischemic Conditioning in Patients With Acute Stroke (RESIST) |
| Arm D - Ivermectin 600 vs Arm D - Placebo: deaths from any cause | 1 of 708 0 of 724 | 0.1 points -0.4 to 0.8 | 1,432 | NCT05894538 ACTIV-6: COVID-19 Study of Repurposed Medications - Arm D (Ivermectin 600) |
| Arm D - Ivermectin 600 vs Arm D - Placebo: serious adverse events | 6 of 708 4 of 724 | 0.3 points -0.7 to 1.3 | 1,432 | NCT05894538 ACTIV-6: COVID-19 Study of Repurposed Medications - Arm D (Ivermectin 600) |
| Short Storage vs Standard Issue: deaths from any cause | 49 of 716 45 of 714 | 0.5 points -2.1 to 3.1 | 1,430 | NCT01977547 Age of Blood in Children in Pediatric Intensive Care Units |
| Short Storage vs Standard Issue: Mortality | 49 of 716 45 of 714 | 0.5 points -2.1 to 3.1 | 1,430 | NCT01977547 Age of Blood in Children in Pediatric Intensive Care Units |
| Arm D - Ivermectin 600 vs Arm D - Placebo: Number of Participants With Mortality | 1 of 708 0 of 722 | 0.1 points -0.4 to 0.8 | 1,430 | NCT05894538 ACTIV-6: COVID-19 Study of Repurposed Medications - Arm D (Ivermectin 600) |
| Arm D - Ivermectin 600 vs Arm D - Placebo: Number of Participants With Hospitalization or Death | 7 of 708 2 of 722 | 0.7 points -0.2 to 1.8 | 1,430 | NCT05894538 ACTIV-6: COVID-19 Study of Repurposed Medications - Arm D (Ivermectin 600) |
| Arm D - Ivermectin 600 vs Arm D - Placebo: Number of Participants With Hospitalization, Urgent Care, Emergency Room Visit, or Death | 39 of 708 42 of 722 | -0.3 points -2.7 to 2.1 | 1,430 | NCT05894538 ACTIV-6: COVID-19 Study of Repurposed Medications - Arm D (Ivermectin 600) |
| Tiotropium Treatment - MAT1 vs Glycopyrronium Treatment - MAT2: deaths from any cause | 52 of 665 67 of 765 | -0.9 points -3.8 to 2.0 | 1,430 | NCT06053541 Morbid Rates After Spiriva Chronic Obstructive Pulmonary Disease (COPD) Protocol Change |
| Edoxaban vs Vitamin K Antagonist (VKA): Number of Participants Who Experienced Major Bleeding (Adjudicated Data) Based on ISTH Criteria in Participants Taking Edoxaban vs VKA | 98 of 713 68 of 713 | 4.2 points 0.9 to 7.6 | 1,426 | NCT02943785 Edoxaban Compared to Standard Care After Heart Valve Replacement Using a Catheter in Patients With Atrial Fibrillation (ENVISAGE-TAVI AF) |
| Edoxaban vs Vitamin K Antagonist (VKA): Number of Participants Who Experienced Myocardial Infarctions (MI) in Participants Taking Edoxaban vs VKA (Adjudicated Data) | 12 of 713 7 of 713 | 0.7 points -0.6 to 2.0 | 1,426 | NCT02943785 Edoxaban Compared to Standard Care After Heart Valve Replacement Using a Catheter in Patients With Atrial Fibrillation (ENVISAGE-TAVI AF) |
| Edoxaban vs Vitamin K Antagonist (VKA): Number of Participants Who Experienced Major Adverse Cardiac Events (MACE) in Participants Taking Edoxaban vs VKA (Adjudicated Data) | 61 of 713 53 of 713 | 1.1 points -1.7 to 4.0 | 1,426 | NCT02943785 Edoxaban Compared to Standard Care After Heart Valve Replacement Using a Catheter in Patients With Atrial Fibrillation (ENVISAGE-TAVI AF) |
| Edoxaban vs Vitamin K Antagonist (VKA): Number of Participants Who Experienced Major Adverse Cardiac and Cerebrovascular Events (MACCE) in Participants Taking Edoxaban vs VKA (Adjudicated Data) | 86 of 713 80 of 713 | 0.8 points -2.5 to 4.2 | 1,426 | NCT02943785 Edoxaban Compared to Standard Care After Heart Valve Replacement Using a Catheter in Patients With Atrial Fibrillation (ENVISAGE-TAVI AF) |
| Edoxaban vs Vitamin K Antagonist (VKA): Number of Participants Who Experienced Systemic Embolic Events in Participants Taking Edoxaban vs VKA (Adjudicated Data) | 2 of 713 3 of 713 | -0.1 points -1.0 to 0.6 | 1,426 | NCT02943785 Edoxaban Compared to Standard Care After Heart Valve Replacement Using a Catheter in Patients With Atrial Fibrillation (ENVISAGE-TAVI AF) |
| Edoxaban vs Vitamin K Antagonist (VKA): Number of Participants Who Experienced Net Adverse Clinical Events (Adjudicated Data) Based on ISTH Criteria in Participants Taking Edoxaban vs VKA | 170 of 713 157 of 713 | 1.8 points -2.5 to 6.2 | 1,426 | NCT02943785 Edoxaban Compared to Standard Care After Heart Valve Replacement Using a Catheter in Patients With Atrial Fibrillation (ENVISAGE-TAVI AF) |
| Edoxaban vs Vitamin K Antagonist (VKA): Number of Participants Who Experienced a Composite of Adverse Events in Participants Taking Edoxaban vs VKA (Adjudicated Data) | 151 of 713 123 of 713 | 3.9 points -0.2 to 8.0 | 1,426 | NCT02943785 Edoxaban Compared to Standard Care After Heart Valve Replacement Using a Catheter in Patients With Atrial Fibrillation (ENVISAGE-TAVI AF) |
Code
curl "https://conductscience.org/api/comparisons/v1?page=222"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=222
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT02941614-deaths",
"title": "Distress Screening vs No Screening: deaths from any cause",
"summary": "25 of 744 against 16 of 692; risk difference 1.0 points, 95% interval -0.7 to 2.8; NCT02941614, Implementing Systematic Distress Screening in Breast Cancer",
"record": "/library/comparisons/NCT02941614-deaths",
"nct_id": "NCT02941614",
"kind": "deaths",
"participants": 1436,
"risk_difference": {
"value": 0.010480763254397413,
"lower": -0.007247930307557975,
"upper": 0.028351718038538774
},
"group_1": "25 of 744",
"group_2": "16 of 692",
"difference": "1.0 points",
"interval": "-0.7 to 2.8",
"trial_title": "Implementing Systematic Distress Screening in Breast Cancer"
},
{
"id": "NCT00002651-sae",
"title": "Continuous Hormonal Therapy vs Intermittent Hormonal Therapy: serious adverse events",
"summary": "19 of 732 against 10 of 702; risk difference 1.2 points, 95% interval -0.3 to 2.7; NCT00002651, SWOG-9346, Hormone Therapy in Treating Men With Stage IV Prostate Cancer",
"record": "/library/comparisons/NCT00002651-sae",
"nct_id": "NCT00002651",
"kind": "serious-adverse-events",
"participants": 1434,
"risk_difference": {
"value": 0.01171126990799122,
"lower": -0.003280687947063798,
"upper": 0.02734822646874087
},
"group_1": "19 of 732",
"group_2": "10 of 702",
"difference": "1.2 points",
"interval": "-0.3 to 2.7",
"trial_title": "SWOG-9346, Hormone Therapy in Treating Men With Stage IV Prostate Cancer"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=223",
"request_id": "5NZJ69J8BphlLTyk"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
The conductscience.com catalog
One instrument from the ConductScience store with the tests, measures and species it is used for, the papers that used it, and the MeSH topics of those papers.
Open Targets
One drug with its targets, the diseases it is studied for, and the trials that name it, with their comparisons, papers and cognitive tests.
Open Targets
One disease with the drugs studied for it, the targets those drugs act on, and the trials that study it, with their comparisons and papers.
ClinicalTrials.gov
One company with the trials it leads or helps run, the drugs those trials test, the conditions they study and the organizations it runs them with.
Cellosaurus
One cell line with the problems Cellosaurus records for it, its relatives, the cell banks that hold it, and the papers that used it.
PubMed and NLM's journal list
One journal with its papers in PubMed since 1959, year by year, its retracted papers, errata and expressions of concern, and how many of its papers have a copy in PMC.
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant